BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION |
Keynote Presentation
|
09:00 - 09:30 |
Spatial Analysis in Ulcerative Colitis and Crohn’s Disease
Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb
|
09:30 - 10:00 |
Opportunities for biomarker development in neuroscience
Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.
|
11:45 - 12:15 |
The crucial role of biospecimen management in precision medicine
Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics
|
12:15 - 12:45 |
AI and Multimodal Biomarkers for Personalized Pain Medicine
Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic
|
12:45 - 13:15 |
Lunch and Poster Presentation | One-to-One Networking Meetings
|
13:15 - 14:15 |
ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE |
Identification of cancer cell surface target for antibody drug conjugate development
Ginette Serrero, Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody
|
14:15 - 14:45 |
Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease
Matteo D’Antonio, Assistant Professor, University of California, San Diego
|
14:45 - 15:15 |
Why is monitoring predictive biomarker data so difficult for big pharma?
|
15:15 - 15:45 |
Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:45 - 16:30 |
Patient Identification and Stratification Applying Predictive Models
|
16:30 - 17:00 |
Use of Real-World Evidence in discovery of digital biomarkers
|
17:00 - 17:30 |
Closing Remarks from the Chairperson
|
17:30 - 17:35 |
Drinks, Reception & Networking
|
17:35 - 18:35 |
Opening Remarks from the Chairperson
Julius Goepp, Founder, CEO, Scaled Microbiomics
|
08:55 - 09:00 |
UNVEILING TOMORROW’S HEALTH WITH NEW MICROBIOME FINDINGS |
Keynote Presentation
|
09:00 - 09:30 |
Interpreting Microbiomes via Multi-Omics in Health, Disease, Aging, and Drug Responses
Julius Goepp, Founder, CEO, Scaled Microbiomics
|
09:30 - 10:00 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
10:30 - 11:15 |
TBA, Senior Representative, Biolog
TBA, Senior Representative, Biolog, ,
|
11:15 - 11:45 |
TBA, Senior Representative, Bioform Solutions
TBA, Senior Representative, Bioform Solutions, ,
|
11:45 - 12:15 |
Oral-Systemic Microbiome Connection and its Modulation
Emily Stein, CEO, Primal Health Inc.
|
12:15 - 12:45 |
Next-Generation Probiotics Against Enteric Pathogen Infection and Chronic Inflammatory Disease
Arun K. Bhunia, Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease
|
12:45 - 13:15 |
Lunch and Poster Presentation | One-to-One Networking Meetings
|
13:15 - 14:15 |
REVOLUTIONIZING WELLNESS – EXPLORING THE FUTURE OF MICROBIOME AND PROBIOTICS |
How Lifestyle and Life Stages affect Gut Microbiota and the power of Biotics.
Miguel Freitas, Vice President - Scientific Affairs, Danone
|
14:15 - 14:45 |
Effect of Lactobacillus Johnsonii 456 on Inflammation Caused Diseases, Cardiovascular Disease, Cancer, Diabetes and Obesity
Robert Schiestl, Director and Manager, Microbio Pharma
|
14:45 - 15:15 |
Working with live probiotics – insights in developing effective skincare products from formulator’s perspective
Maya Ivanjesku, Chief Scientific Officer, M2B Pharma
|
15:15 - 15:45 |
Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:45 - 16:30 |
Back to Health - An Evolutionary Biology Perspective on the Skin Microbiome
|
16:30 - 17:00 |
Modulation of the Aging Gut Microbiome to Improve Health
|
17:00 - 17:30 |
Closing Remarks from the Chairperson
Julius Goepp, Founder, CEO, Scaled Microbiomics
|
17:30 - 17:35 |
Drinks Reception & Networking
|
17:35 - 18:35 |
NEW ANTIBODIES DEVELOPMENT AND TUMOR MICRO-ENVIRONMENT |
Identification of potential patient selection biomarkers for the treatment of cancer with tivumecirnon (FLX475) in combination with anti-PD-1
Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics
|
09:30 - 10:00 |
TBA, Senior Representative, Volition
TBA, Senior Representative, Volition, ,
|
10:00 - 10:30 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
10:30 - 11:15 |
Case Studies Leveraging 20,000 Digitized IO KM Curves – Interactive Analysis and Real-Time Insights at the Forefront of Immuno-Oncology
Bruno Larvol, Founder & CEO, Larvol
|
11:15 - 11:45 |
Recombinant antibodies for Immunotherapy
|
11:45 - 12:15 |
Challenges in the clinical development of ADC’s
|
12:15 - 12:45 |
Spatial Analytics of the TME and Discovering Spatial Biomarkers for Immunotherapy
Arvind Rao, Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor
|
12:45 - 13:15 |
Lunch and Poster Presentation | One-to-One Networking Meetings
|
13:15 - 14:15 |
DEVELOPMENTS IN CAR-T AND T-CELL THERAPIES PERSONALIZED IMMUNOTHERAPY |
Solution Provider Presentation
|
14:15 - 14:45 |
Precision Immunology for targeted therapy
|
14:45 - 15:15 |
Role of Cancer Microbiome in IO
|
15:15 - 15:45 |
Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:45 - 16:30 |
CAR-T cell therapy in solid tumours
|
16:30 - 17:00 |
Panel Discussions
|
17:00 - 17:30 |
Closing Remarks from the Chairperson
|
17:30 - 17:35 |
Drinks Reception & Networking
|
17:35 - 18:35 |
|